FCCC LOGO Faculty Publications
Management of Metastatic Colorectal Carcinoma in Older Adults: Balancing Risks and Benefits of Novel Therapies
Drugs Aging. 2021 aug;38(8) :639-654
Back to previous list
Abstract
The prevalence of older patients with metastatic colorectal cancer (mCRC) will continue to increase with our aging population. Treatment of mCRC has changed significantly in the last few decades as we have learned how to personalize the treatment of mCRC to the biology of the tumor, utilizing new treatment approaches. With an ever-changing treatment paradigm, managing the population of older adults becomes paramount. This review highlights the pivotal clinical trials that defined the use of systemic therapy, immunotherapy and targeted therapies for mCRC, and how those are applied to the older patient population. In addition, we outline the tools for an in-depth assessment of an older adult in regards to treatment planning and management of therapy-related toxicities. A comprehensive geriatric assessment can assist in the selection of treatment for an older adult with mCRC. While frail older patients can frequently only tolerate single agents or modified regimens, fit older adults remain candidates for a wider range of treatment options. However, since all of these treatments are associated with possible toxicities, each patient's treatment must be personalized to the patient's goals and wishes through a shared decision-making process.
Notes
1179-1969 Correa, Erika Lindsay, Timothy Dotan, Efrat Orcid: 0000-0002-5762-512x Cancer Center Support Grant 3 P30 CA006927/Foundation for the National Institutes of Health/ Journal Article Review New Zealand Drugs Aging. 2021 Jun 18. doi: 10.1007/s40266-021-00869-z.